{"entity":{"id":"paper-santosh-kesari-nat-commun-2026","kind":"paper","name":"Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations","aka":[],"tldr":"Paper by Santosh Kesari indexed on Europe PMC as PubMed record 41501023, in Nature Communications (2026), one of the most cited records naming an author with this name at Asthra Health.","summary":"Glioblastoma (GBM) remains the most common and lethal adult malignant primary brain cancer with few treatment options. A significant issue hindering GBM therapeutic development is intratumor heterogeneity and plasticity. GBM tumors contain neoplastic cells within a fluid spectrum of diverse transcriptional states. Identifying effective therapeutics requires a platform that predicts the differential sensitivity and resistance of these states to various treatments. Here, we develop scFOCAL (Single-Cell Framework for -Omics Connectivity and Analysis via L1000), to quantify the cellular drug sensitivity and resistance landscape. Using single-cell RNA sequencing of newly diagnosed and recurrent GBM tumors, we identify compounds from the LINCS L1000 database with transcriptional response signatures selectively discordant with distinct GBM cell states, and leverage this capability to predict combination synergy. We validate the significance of these findings in vitro, ex vivo, and in vivo, and identify a combination of an OLIG2 inhibitor and Depatux-M for the treatment of GBM. Our studies suggest that scFOCAL identifies cell states that are sensitive and resistant to targeted therapies in GBM using a measure of cell and drug connectivity, which can be applied to identify new synergistic combinations.\n\nIndexed on Europe PMC as PubMed record 41501023 (DOI 10.1038/s41467-025-67783-5). Its author list gives \"Kesari S\" with the affiliation \"Asthra Health and Lundquist Institute, Santa Monica, CA, USA\", which names Asthra Health; that is how the record was matched to Santosh Kesari, and no figure has been checked by an editor.","asOf":"2026-09-22","links":[{"label":"Nat Commun 2026","url":"https://doi.org/10.1038/s41467-025-67783-5"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/41501023/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/41501023"}],"tags":["europepmc-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["santosh-kesari"],"bottlenecks":[],"keyPapers":[],"journals":["nature-communications"],"dependsOn":[],"notes":[],"journal":"Nature Communications","year":2026,"doi":"10.1038/s41467-025-67783-5","pmid":"41501023","authors":"Suter RK, Jermakowicz AM, Veeramachaneni R, et al.","paperType":"basic","findings":[],"whatItMeans":"One of the most cited papers Europe PMC returns for Santosh Kesari at Asthra Health, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.","caveats":["Matched to the person by surname, initials and an affiliation string naming the institution on the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.","Two authors sharing a surname, initials and institution cannot be told apart by this method; the person's profile links are the place to confirm authorship."]},"route":"/key-papers/paper-santosh-kesari-nat-commun-2026/","neighbours":{"person":[{"id":"santosh-kesari","kind":"person","name":"Santosh Kesari","route":"/people/santosh-kesari/"}],"journal":[{"id":"nature-communications","kind":"journal","name":"Nature Communications","route":"/journals/nature-communications/"}]}}